Recent amendments have been made to the Ontario Regulation 201/96 under the Ontario Drug Benefit Act (‘ODBA Regulation’) and to Regulation 935 under the Drug Interchangeability and Dispensing Fee Act (‘DIDFA Regulation’). The amendments have been approved by the Ontario Government and come into force on October 1, 2016. A notice ... Read More


To help drug manufacturers prepare drug submissions, the Ministry of Health and Long-Term Care has updated its Ontario Guidelines for Drug Submission and Evaluation (Guidelines). The Guidelines take effect on October 6, 2016. All submissions received on or after this date must comply. The updated Guidelines reflect current regulatory and policy requirements ... Read More


The British Columbia PharmaCare (BC PharmaCare) is modernizing the Reference Drug Program (RDP). Effective immediately, transitional coverage is in place to allow affected patients to switch drugs, if needed, to retain full PharmaCare coverage. During transition, PharmaCare will cover all Modernized RDP fully covered drugs and all original RDP fully ... Read More


The Régie de l’assurance maladie du Québec (RAMQ) is scheduled to release its June update of the List of Medications on June 13, 2016 which will come into effect on June 15, 2016. For more information and to see the list update schedule, please visit the RAMQ website.


Effective June 1, 2016, the Nova Scotia Pharmacare will begin funding INFLECTRA™ (infliximab) as an exception status benefit. For infliximab-naïve patients whose infliximab therapy is initiated after June 1, 2016, Inflectra will be the product approved for the following indications: Rheumatoid Arthritis Ankylosing Spondylitis Psoriasis Criteria Updates – Rheumatoid Arthritis The Atlantic ... Read More


To meet the needs of Quebec’s Ministry of Health and Social Services (MSSS), the Institut national d’excellence en santé et en services sociaux (INESSS) has developed a new drug review process for stable blood products for their addition to the Liste des produits du système du sang du Québec. In addition, ... Read More


Effective April 1, 2016, all drug products reviewed by the Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR) will no longer require a routine review by the Committee to Evaluate Drugs (CED), the Ontario Ministry of Health and Long-Term Care’s expert drug advisory committee. This change also ... Read More


The Ontario Public Drug Programs (OPDP) began funding INFLECTRA™ (infliximab) as a Limited Use (LU) benefit for eligible ODB recipients, effective February 25, 2016, for the following indications: Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis Plaque Psoriasis The LU criteria are posted in the eFormulary which can found on the ministry’s website at: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx The funding of ... Read More


The Ontario Ministry of Health and Long-Term Care (the ‘ministry’) is proposing to update recipient cost-sharing arrangements for non-low income seniors as well as expand eligibility for the Seniors Co-Payment Program under the Ontario Drug Benefit (ODB) program. Proposed amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act ... Read More


Revised Procedures for CDR and pCODR For all drug applications filed for review through either the Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) process on or after April 1, 2016, CADTH will no longer accept confidential submitted prices. The submitted price will be disclosed in all applicable CDR ... Read More